Baseline characteristics of patients starting secukinumab or a TNFi
| Treatment starts, n | Secukinumab | Adalimumab | Etanercept | Infliximab | Golimumab | Certolizumab | Total |
| 456 | 1006 | 1800 | 783 | 500 | 306 | 4851 | |
| Sex, men, n (%) | 190 (42) | 507 (50) | 909 (51) | 405 (52) | 289 (58) | 124 (41) | 2424 (50) |
| Age, years, mean (SD) | 48 (13) | 44 (14) | 43 (14) | 43 (14) | 43 (14) | 44 (14) | 44 (14) |
| Diagnosis, AS n (%) | 188 (41) | 413 (41) | 704 (39) | 366 (47) | 258 (52) | 120 (39) | 2049 (42) |
| BASDAI, mean (SD) | 6.4 (2.0) | 5.5 (2.1) | 5.5 (2.0) | 5.8 (2.0) | 5.3 (2.3) | 5.9 (2.1) | 5.6 (2.1) |
| Missing n (%) | 248 (54) | 622 (62) | 1053 (59) | 462 (59) | 283 (57) | 190 (62) | 2858 (59) |
| ASDAS, mean (SD) | 3.4 (1.0) | 3.0 (1.0) | 3.0 (0.9) | 3.2 (1.0) | 3.0 (1.0) | 3.2 (1.0) | 3.1 (1.0) |
| Missing n (%) | 257 (56) | 669 (67) | 1156 (64) | 486 (62) | 301 (60) | 197 (64) | 3066 (63) |
| Patient global assessment, mean (SD) | 67 (21) | 57 (23) | 58 (22) | 59 (23) | 56 (24) | 61 (23) | 59 (23) |
| Missing n (%) | 194 (43) | 500 (50) | 881 (49) | 391 (50) | 230 (46) | 142 (46) | 2338 (48) |
| CRP, mean (SD) | 11 (22) | 10 (16) | 10 (16) | 15 (29) | 11 (20) | 10 (16) | 11 (20) |
| Missing n (%) | 185 (41) | 462 (46) | 799 (44) | 329 (42) | 208 (42) | 120 (39) | 2103 (43) |
| Line of bDMARD treatment | |||||||
| Line 1, n (%) | 35 (8) | 470 (47) | 1202 (67) | 539 (69) | 242 (48) | 79 (26) | 2567 (53) |
| Line 2, n (%) | 106 (23) | 347 (34) | 415 (23) | 100 (13) | 112 (22) | 96 (31) | 1176 (24) |
| Line 3, n (%) | 129 (28) | 109 (11) | 93 (5) | 86 (11) | 76 (15) | 65 (21) | 558 (12) |
| Line ≥4, n (%) | 186 (41) | 80 (8) | 90 (5) | 58 (7) | 70 (14) | 66 (22) | 550 (11) |
| IBD, n (%) | 16 (4) | 109 (11) | 45 (3) | 69 (9) | 28 (6) | 21 (7) | 288 (6) |
| Psoriasis, n (%) | 62 (14) | 70 (7) | 112 (6) | 44 (6) | 34 (7) | 34 (11) | 356 (7) |
| Previous AU, n (%)* | 63 (14) | 179 (18) | 204 (11) | 96 (12) | 88 (18) | 50 (16) | 680 (14) |
| Concomitant csDMARDs | |||||||
| Methotrexate, n(%) | 73 (16) | 168 (17) | 255 (14) | 215 (27) | 77 (15) | 47 (15) | 835 (17) |
| Sulfasalazine, n (%) | 27 (6) | 80 (8) | 164 (9) | 71 (9) | 41 (8) | 30 (10) | 413 (9) |
| csDMARD total, n (%) | 102 (22) | 251 (25) | 414 (23) | 282 (36) | 119 (24) | 82 (27) | 1250 (26) |
The table presents the data for the ‘main cohort’, excluding cases with a diagnosis of AU in the year prior to treatment start. Data were complete unless otherwise presented.
*Any registration of AU in outpatient ophthalmology care since start of the outpatient register in 2001.
AS, ankylosing spondylitis; ASDAS, Ankylosing Spondylitis Disease Activity Score; AU, anterior uveitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; bDMARD, biological disease modifying anti-rheumatic drug; CRP, C reactive protein; csDMARD, conventional synthetic DMARD; IBD, inflammatory bowel disease; TNFi, tumour necrosis factor inhibitors.